Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2024-04-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2024. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for the quarter ending March 31, 2024. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is IR.
2024-04-29 Chinese
百奥泰 自愿披露关于TOFIDENCE（托珠单抗注射液）获欧洲药品管理局人用药品委员会积极意见的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on the drug TOFIDENCE (a biosimilar monoclonal antibody). It details the drug's approval status in various regions, partnership agreements, and potential market impact. The document is relatively short (1587 characters) and serves as a voluntary disclosure or announcement about regulatory progress and business impact rather than a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention the release or availability of a report. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval progress and business implications that does not fit into more specific categories like Capital/Financing Update or Legal Proceedings.
2024-04-26 Chinese
百奥泰 2023年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of 百奥泰生物制药股份有限公司. It discusses the legality and validity of the AGM's convening, voting procedures, participants' qualifications, and voting results. The document does not contain financial statements or detailed financial performance data but focuses on the procedural and legal aspects of the AGM. It is not the AGM presentation materials themselves but a legal opinion related to the AGM. Given the content and purpose, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the legality and validity of the AGM voting process and results. The document length is under 5,000 characters, but it is a substantive legal opinion rather than a mere announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is DVA with high confidence.
2024-04-18 Chinese
百奥泰 2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" from 百奥泰生物制药股份有限公司. It details the date and location of the AGM, attendance, voting results on various proposals including the 2023 annual report, board and supervisory reports, financial statements, profit distribution, remuneration plans, auditor appointment, credit application, and share issuance authorization. It also includes legal witness statements confirming the legality of the meeting and voting procedures. The document primarily reports the official voting results and resolutions passed at the AGM rather than the full annual report or financial statements themselves. The document length is 3835 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2024-04-18 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司首次公开发行股票并在科创板上市之持续督导保荐总结报告书
Regulatory Filings
2024-04-12 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2023年度持续督导跟踪报告
Regulatory Filings
2024-04-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.